Injection-Site Nodules Associated With the Use of Exenatide Extended-Release Reported to the U.S. Food and Drug Administration Adverse Event Reporting System

Registos relacionados

• Persistent injection site nodules from exenatide: Successful treatment with intralesional triamcinolone
  Por: Riswold, Kayla, et al.
  Publicado em: (2018)
• Eosinophilic Panniculitis Following the Subcutaneous Injection of Exenatide Extended-Release
  Por: Ko, Jung-Woo, et al.
  Publicado em: (2020)
• Comparison of Brand versus Generic Antiepileptic Drug Adverse Event Reporting Rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)
  Por: Rahman, Md. Motiur, et al.
  Publicado em: (2017)
• Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System
  Por: Raschi, Emanuel, et al.
  Publicado em: (2019)
• Methodological considerations for comparison of brand versus generic versus authorized generic adverse event reports in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)
  Por: Rahman, Md. Motiur, et al.
  Publicado em: (2017)